Salute e Benessere
The Lancet Publishes Results from World's Largest Coronary CT Registry Showing New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation At Least 10 Years in Advance
Key study findings include:
"The study is an expanding global registry which will include long-term clinical and outcome data for 250,000 patients from around the world, and we are very pleased to publish these initial results," said , MD, Professor of Cardiovascular Medicine at the University of Oxford , Caristo's Chief Medical Officer, and co-author of publication. "Coronary inflammation is a crucial piece of the puzzle in predicting heart attack risk. We are excited to discover that results performed exceptionally well in predicting patient cardiac events. This tool is well positioned to help clinicians identify high-risk patients with seemingly 'normal' CCTA scans."
, MD, Professor of Medicine and Radiology at Harvard Medical School , Director of Cardiac Computed Tomography at Brigham and Women's Hospital, and co-author of the publication, commented: "This study, which represents one of the largest studies in the field of CCTA, has important implications for the field of preventive cardiology. I am excited about the potential of the biomarker, which has promising prognostic value beyond existing CT-based methods such as plaque, calcium scoring, and CAD-RADS based interpretation."
The study underlines the need for a robust risk prediction tool that can identify vulnerable patients with inflamed coronary arteries, particularly in those without obstructive CAD. This approach would transform CCTA from a test used to triage a minority of patients for further intervention into a prevention tool that guides management for all patients undergoing CCTA.
On June 27 at 11am EDT , the Society of Cardiovascular Computed Tomography (SCCT) will host a webinar on
publication findings to be presented by the lead author, Prof.
Charalambos Antoniades , and joined by several co-authors (Prof. Channon, Prof.
Stefan Neubauer , Prof.
Ed Nicol , Prof. Blankstein and Prof. Milind Desai ). The webinar will present the key results from
publication along with a panel discussion on the implications of this landmark study. Check
in early June for the webinar registration link.
Caristo's patented technology marks a scientific breakthrough that is radically transforming the traditional approach to heart disease prediction, prevention and management. The technology applies advanced AI algorithms to routine coronary computed tomography angiography (CCTA) scans to visualize and quantify coronary inflammation, the otherwise invisible disease mechanism responsible for many fatal heart attacks and strokes. Prior to this publication by , earlier validation results showing technology's ability to aid the prediction of heart attacks were published in leading medical journals including the Lancet, JACC, European Heart Journal, and Cardiovascular Research.
The ® technology is in clinical use in the UK, European Union, and Australia .
is a global leader in cardiac and vascular disease diagnostics and risk prediction. Founded in 2018 as a spin-out company from the University of Oxford , the world's #1 research university, Caristo has developed a portfolio of imaging-based and AI-assisted platforms that can be applied to aid the prediction and diagnosis of heart attack, stroke, and diabetes. Caristo has been recognized by Newsweek as one of the best digital health companies, and highlighted by as one of the most exciting science-based companies to have emerged from academic labs. Find Caristo online on its , and .
Logo: https://mma.prnewswire.com/media/2054669/4734272/Caristo_Logo.jpg
Frank Cheng , Caristo Diagnostics CEO
info@caristo.com
View original content:https://www.prnewswire.co.uk/news-releases/the-lancet-publishes-results-from-worlds-largest-coronary-ct-registry-showing-new-ai-technology-can-predict-cardiac-events-due-to-coronary-inflammation-at-least-10-years-in-advance-302159435.html